43
Participants
Start Date
May 3, 2021
Primary Completion Date
November 10, 2023
Study Completion Date
November 10, 2023
Selexipag
Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
Kaohsiung Veterans General Hospital, Kaohsiung City
National Taiwan University Hospital, Taipei
Gachon University Gil Medical Center, Incheon
The Republican Scientific-Practical Center ''Cardiology'', Minsk
Minsk Regional Clinical Hospital, Minsk
Sanjivani Hospitals, Ahmedabad
Apollo Hospitals, Chennai
Institutul de pneumoftiziologie Marius Nasta, Bucharest
Samsung Medical Center, Seoul
The Catholic University of Korea Seoul St Marys Hospital, Seoul
Municipal Inst. Of Dnipropetrovsk Region. Council, Dnipro
Health Care Municipal Institution City Clinical Hospital #13, Kharkiv
State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kyiv
Lead Sponsor
Actelion
INDUSTRY